Matthew Reaney

Matthew Reaney

Auto-generated profile, based on publicly available information

Matthew Reaney

IQVIA, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
EZErica Zaiser
Erica Zaiser
ASAmy J. Sehnert
Amy J. Sehnert
ADAshley Duenas
Ashley Duenas
SSSara Saberi
Sara Saberi
EBElla Brookes
Ella Brookes
MRMatthew Reaney
Matthew Reaney
Background: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients’ perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients’ experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them. Methods: Development of the HCM conceptual model involved a web-based survey to capture patients’ insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients’ experiences were identified and used to develop a conceptual model of the patient experience with HCM. Results: The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients’ lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM. Conclusions: A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients’ lives. This HCM conceptual model reflecting patients’ experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.

31 July 2022 in European Journal of Cancer
Verified
Journal Article
Open access
AOAna Oaknin
Ana Oaknin
BMBradley J. Monk
Bradley J. Monk
IVIgnace Vergote
Ignace Vergote
AMAndreia C. De Melo
Andreia C. De Melo
YKYong-Man Kim
Yong-Man Kim
KTKrishnansu S. Tewari
Krishnansu S. Tewari
In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9; R2810-ONC-1676; NCT03257267) and cemiplimab significantly improved survival versus investigator's choice of chemotherapy among patients with recurrent cervical cancer who had progressed on platinum-based therapy. Here we report patient-reported outcomes in this pivotal study. Patients were randomised 1:1 to open-label cemiplimab (350 mg intravenously every 3 weeks) or investigator's choice of chemotherapy in 6-week cycles. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 during cycles 1-16. Least-squares mean changes from baseline in global health status (GHS)/quality of life (QoL) and physical functioning (PF) were secondary end-points in the statistical hierarchy. Of 608 patients (304/arm), 77.8% patients had squamous cell carcinoma and 22.2% patients had adenocarcinoma. Questionnaire completion rates were ∼90% throughout. In the squamous cell carcinoma population, overall between-group differences statistically significantly favoured cemiplimab in GHS/QoL (8.49; 95% confidence interval [CI]: 3.77-13.21; P = 0.0003) and PF (8.35; 95% CI: 4.08-12.62; P < 0.0001). Treatment differences favoured cemiplimab in both histologic populations by cycle 2. Overall changes from baseline in most functioning and symptom scales favoured cemiplimab, with clinically meaningful treatment differences in role functioning, appetite loss and pain in both populations. The sensitivity analyses, responder analyses and time to definitive deterioration favoured cemiplimab in both populations. Cemiplimab conferred favourable differences in GHS/QoL and PF compared with chemotherapy among patients with recurrent cervical cancer, with benefits in PF by cycle 2, and clinically meaningful differences favouring cemiplimab in role functioning, appetite loss, and pain.

19 June 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
VSVibeke Strand
Vibeke Strand
LGLaure Gossec
Laure Gossec
CPClare W. J. Proudfoot
Clare W. J. Proudfoot
CCChieh-I Chen
Chieh-I Chen
MRMatthew Reaney
Matthew Reaney
GBGerd Ruediger Burmester
Gerd Ruediger Burmester
The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monotherapy in reducing disease activity and signs and symptoms of RA, as well as in improving physical function, with similar rates of adverse and serious adverse events. We report the effects of sarilumab versus adalimumab on patient-reported outcomes (PROs). Patients with active RA intolerant of, or inadequate responders to, methotrexate were randomized to sarilumab 200 mg plus placebo every 2 weeks (q2w; n = 184) or adalimumab 40 mg plus placebo q2w (n = 185). Dose escalation to weekly administration of adalimumab or matching placebo was permitted at week 16. PROs assessed at baseline and weeks 12 and 24 included patient global assessment of disease activity (PtGA), pain and morning stiffness visual analogue scales (VASs), Health Assessment Questionnaire Disability Index (HAQ-DI), 36-item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Rheumatoid Arthritis Impact of Disease (RAID), and rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Between-group differences in least-squares mean (LSM) changes from baseline were analyzed. p < 0.05 was considered significant for PROs in a predefined hierarchy. For PROs not in the hierarchy, nominal p values are provided. Proportions of patients reporting improvements greater than or equal to the minimal clinically important difference (MCID) and achieving normative values were assessed. At week 24, sarilumab treatment resulted in significantly greater LSM changes from baseline than adalimumab monotherapy in HAQ-DI (p < 0.005), PtGA (p < 0.001), pain VAS (p < 0.001), and SF-36 Physical Component Summary (PCS) (p < 0.001). Greater LSM changes were reported for sarilumab than for adalimumab in RAID (nominal p < 0.001), morning stiffness VAS (nominal p < 0.05), and WPS-RA (nominal p < 0.005). Between-group differences in FACIT-F and SF-36 Mental Component Summary (MCS) were not significant. More patients reported improvements greater than or equal to the MCID in HAQ-DI (nominal p < 0.01), RAID (nominal p < 0.01), SF-36 PCS (nominal p < 0.005), and morning stiffness (nominal p < 0.05), as well as greater than or equal to the normative values in HAQ-DI (p < 0.05), with sarilumab versus adalimumab. In parallel with the clinical efficacy profile previously reported, sarilumab monotherapy resulted in greater improvements across multiple PROs than adalimumab monotherapy. ClinicalTrials.gov, NCT02332590 . Registered on 5 January 2015.

1 November 2013 in Diabetes Spectrum
Verified
Journal Article
Open access
PDF file
MRMatthew Reaney
Matthew Reaney
EZEsther Gil Zorzo
Esther Gil Zorzo
AGAlain Golay
Alain Golay
NHNorbert Hermanns
Norbert Hermanns
SCSimon Cleall
Simon Cleall
VKVeikko Koivisto
Veikko Koivisto
Objective. This study compared the effectiveness of Conversation Map™ (CM) education tools versus regular care of adults with type 2 diabetes. Methods. Participants from Spain and Germany were randomized to either four CM education sessions or regular care. Data were collected at baseline (visit 1), immediately post-education (visit 2), and 6 months later (visit 3). The primary objective was to compare diabetes knowledge between education groups at visit 3, using the Audit of Diabetes Knowledge (ADKnowl) questionnaire (score range 0–100). Results. Of 681 participants randomized (CM 330, regular care 351), 91.8% completed visit 3. Median ADKnowl scores increased significantly (P < 0.001) in both groups (CM visit 1, 60.3; visit 2, 73.5; and visit 3, 72.5; regular care visit 1, 63.3; visit 2, 73.5; and visit 3, 73.6). At visit 3, scores were not ranked significantly differently between education groups (P = 0.284). In Spain (n = 310), visit 3 scores were ranked higher for CM than for regular care (P < 0.001); in Germany (n = 371), the opposite was true (P < 0.001). Of participants receiving regular care, 78.3% of those in Germany and 13.5% of those in Spain had non-CM structured education between visits 1 and 2. In Spain, CM patients had higher satisfaction with care and goal attainment than regular-care patients at visit 2 (visit 2 P < 0.001, visit 3 P = 0.055). In Germany, CM patients had less emotional distress than regular-care patients (visit 2 P = 0.025, visit 3 P = 0.003). Median A1C decreased similarly in both groups and countries. Conclusion. Diabetes knowledge and clinical outcomes improved in both education groups. At visit 3, diabetes knowledge in the CM group was not ranked higher than in the regular-care group. In Germany, where regular care frequently involves structured education programs, diabetes knowledge was ranked higher with regular care than with CM. In Spain, where no structured national diabetes education and awareness programs are in place, scores were ranked higher with CM than with regular care.

1 May 2016 in Transplantation Direct
Verified
Journal Article
Open access
JSJane Speight
Jane Speight
AWAlison J. Woodcock
Alison J. Woodcock
MRMatthew D. Reaney
Matthew D. Reaney
SAStephanie A. Amiel
Stephanie A. Amiel
PJPaul R.v. Johnson
Paul R.v. Johnson
JSJames A.M. Shaw
James A.M. Shaw
For selected individuals with type 1 diabetes, pancreatic islet transplantation (IT) prevents recurrent severe hypoglycemia and optimizes glycemia, although ongoing systemic immunosuppression is needed. Our aim was to explore candidates and recipients' expectations of transplantation, their experience of being on the waiting list, and (for recipients) the procedure and life posttransplant. Cross-sectional qualitative research design using semistructured interviews with 16 adults (8 pretransplant, 8 posttransplant; from 4 UK centers (n = 13) and 1 Canadian center (n = 3)). Interviews were audio-recorded, transcribed, and underwent inductive thematic analysis. Interviewees were aged (mean ± SD) 52 ± 10 years (range, 30-64); duration of diabetes, 36 ± 9 years (range, 21-56); 12 (75%) were women. Narrative accounts centered on expectations, hopes, and realities; decision-making; waiting and uncertainty; the procedure, hospital stay, and follow-up. Expected benefits included fewer severe hypoglycemic episodes, reduced need for insulin, preventing onset/progression of complications and improved psychological well-being. These were realized for most, at least in the short term. Most interviewees described well-informed, shared decision-making with clinicians and family, and managing their expectations. Although life "on the list" could be stressful, and immunosuppressant side effects were severe, interviewees reported "no regrets." Posttransplant, interviewees experienced increased confidence, through freedom from hypoglycemia and regained glycemic control, which tempered any disappointment about continued reliance on insulin. Most viewed their transplant as a success, though several reflected upon setbacks and hidden hopes for becoming "insulin-free." Independently undertaken interviews demonstrated realistic and balanced expectations of IT and indicate how to optimize the process and support for future IT candidates.

15 March 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
LGLaure Gossec
Laure Gossec
VSVibeke Strand
Vibeke Strand
CPClare Proudfoot
Clare Proudfoot
CCChieh-I Chen
Chieh-I Chen
SGSophie Guillonneau
Sophie Guillonneau
MRMatthew Reaney
Matthew Reaney
Objective.: We evaluated the effect of sarilumab on patient-perceived impact of rheumatoid arthritis (RA) using the 7-domain RA Impact of Disease (RAID) scale. Methods.: Two phase III, randomized, controlled trials of sarilumab in patients with active, longstanding RA were analyzed: (1) sarilumab 150 mg and 200 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARD) versus placebo + csDMARD [TARGET ( NCT01709578 )]; and (2) sarilumab 200 mg versus adalimumab (ADA) 40 mg monotherapy [MONARCH ( NCT02332590 )]. Least-squares mean (LSM) differences in RAID total score (range 0–10) and 7 key RA symptoms, including pain and fatigue (baseline to Weeks 12 and 24), were compared. “Responders” by RAID total score were defined by improvements from baseline ≥ minimal clinically important difference (MCID), and ≥ patient-acceptable symptom-state (PASS) at endpoint. Results.: Sarilumab 150 mg and 200 mg + csDMARD were nominally superior (p < 0.05) versus placebo + csDMARD and 200 mg sarilumab versus ADA 40 mg in LSM differences for RAID total score at weeks 12 (−0.93 and −1.13; −0.49, respectively) and 24 (−0.75 and −1.01; −0.78), and all effects of RA (except functional impairment in MONARCH Week 12). Effects were greater in physical domains (e.g., pain) than mental domains (e.g., emotional well-being). More patients receiving sarilumab versus placebo or ADA reported improvements ≥ MCID and PASS in total RAID scores at both assessments. Conclusion.: Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients’ lives to a greater extent than placebo + csDMARD or ADA monotherapy. ( ClinicalTrials.gov : NCT01709578 and NCT02332590 )